The Division of Hematology/Oncology/Blood and Marrow Transplantation (BMT) at Nationwide Children’s Hospital treats patients with any one of a full array of blood disorders, cancers, immunodeficiency disorders, bone marrow failure syndromes and inherited metabolic storage diseases. Our clinical team oversees the comprehensive evaluation, multidisciplinary diagnosis, treatment and long-term management of children, adolescents and young adults with blood disorders and cancer as well as other diseases treated by cellular therapies.
In addition to clinical care, through our integrated programs with The Research Institute’s Center for Childhood Cancer and Blood Diseases at Nationwide Children’s and the Biopathology Center at Nationwide Children’s, we seek to transform the way patients with cancer and blood disorders are cared for by fully integrating research, cutting-edge therapies and multidisciplinary teams.
The Division of Hematology, Oncology and Blood and Marrow Transplant (BMT) is committed to advancing both basic and clinical research. The division works hand-in-hand with the Center for Childhood Cancer and Blood Diseases at Nationwide Children’s to expand the understanding of childhood cancer and to improve strategies for its diagnosis and treatment. We offer the latest treatment options and new clinical trials to our patients. The division is expanding in the area of experimental therapeutics, offering patients more access to phase I and phase II studies, including both industry-sponsored and investigator-initiated trials. Total inpatient admissions and outpatient visits have been growing in recent years, and we now exceed 13,000 annually, distinguishing the division as one of the largest in the United States.
A prime example of our outstanding programs is our brain and spinal tumor program, with a vision for improving the treatment and outcomes of children and adolescents with central nervous system tumors. Jonathan L. Finlay, MB, ChB, FRCP, joined our team this year as the medical director of the Neuro-Oncology Program at Nationwide Children’s. Dr. Finlay is a professor of pediatrics at The Ohio State University College of Medicine and an internationally recognized authority in the management of childhood brain tumors. He has led our efforts to create a unique, stand-alone multidisciplinary neurooncology tumor board, neuro-oncology pathology rounds, international virtual tumor board and consultative service in real-time, and a fourth year neuro-oncology fellowship training program.
Dr. Finlay pioneered the treatment of pediatric brain tumors with high-dose chemotherapy and autologous blood cell transplantation to improve outcomes for patient with recurrent malignant brain tumors. He has a special interest in minimizing the negative longterm neurocognitive consequences of radiation therapy. Dr. Finlay’s clinical approach has been studied in a series of three prospective multinational “Head Start” clinical trials, the fourth of which will be coordinated through Nationwide Children’s National Experimental Therapeutics (NEXT) Consortium. NEXT is a collaborative research model for investigator-initiated studies that contribute to the early development of promising new therapies for childhood cancer and blood disorders.
The Biopathology Center (BPC) aims to excel in long-term acquisition and storage of cancer-related tissue specimens and associated data in support of cutting-edge research. Led by Nilsa Ramirez, MD, and Julie Gastier-Foster, PhD, the BPC is primarily government-funded and collaborates with multiple research organizations to establish a significant infrastructure to support excellence in tissue banking, testing and distribution.
The BCP houses several National Cancer Institute-sponsored cancer biobanks, including the Children’s Oncology Group biobank, the largest pediatric specimen bank in the nation.
Hematology, Oncology and BMT Faculty
Timothy P. Cripe, MD, PhD
Randal S. Olshefski, MD
selected hematology, oncology and bmt publications
Compas B, Desjardina L, Rodriguez E, Dunn M, Bemis H, Vannatta K, Young-Saleme T, Snyder S, Gerhardt C. Children and adolescents coping with cancer: self- and parent reports of coping and anxiety/depression. Health Psychology: Official Journal of the Division of Health Psychology, American Psychological Association. 2014 Aug; 33(8):853-61.
Haworth KB, Leddon JL, Chen CY, Horwitz EM, Mackall CL, Cripe TP. Going back to class I: MCH and immunotherapies for childhood cancer. Pediatric Blood and Cancer. 2015 Apr;62(4):571-6.
Kerlin BA, Waller AP, Sharma R, Chanley MA, Nieman MT, Smoyer WE. Disease severity correlates with thrombotic capacity in experimental nephrotic syndrome. Journal of the American Society of Nephrology: JASN. 2015 Apr 8. [Epub ahead of print].
Khamees D, Kilma J, O’Brien SH. Population screening for von Willebrand’s disease in adolescents with heavy menstrual bleeding. The Journal of Pediatrics. 2015 Jan;166(1):195-7.
O’Brien SH, Kulkarni R, Wallace A, Hamblin F, Burr S, Goldenberg NA. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. Journal of Thrombosis and Haemostasis: JTH. 2014 Nov;12(11):1822-25.
Center for Childhood Cancer and Blood Diseases